FDA Advisory Panel Reviews Tobacco Company’s Proposed Statement
Tobacco company’s proposed statement that ”snus” product users have lower risk of six deadly smoking-related diseases, undergoes FDA advisory panel’s review at February 6 meeting. The United States’ Tobacco Products Scientific Advisory Council (TPSAC) reviewed the amendment for Swedish Match’s Modified Risk Tobacco Product (MRTP) application the morning of February 6, 2019. Why this is […]
Tobacco company’s proposed statement that ”snus” product users have lower risk of six deadly smoking-related diseases, undergoes FDA advisory panel’s review at February 6 meeting.
The United States’ Tobacco Products Scientific Advisory Council (TPSAC) reviewed the amendment for Swedish Match’s Modified Risk Tobacco Product (MRTP) application the morning of February 6, 2019.
Why this is important: The panel’s findings will provide guidance to the U.S. Food and Drug Administration (FDA) on whether they believe FDA should approve the first-ever Modified Risk Tobacco Product (MRTP) to General Snus (rhymes with juice). If FDA approves, Swedish Match would receive the first-ever modified risk marketing claim. The ruling would come likely months in the future.
Visit https://www.fda.gov/AdvisoryCommittees/Calendar/ucm628770.htm for more information.
